Patients
ascites, peristomal infection, malignancy, hepatomegaly, allergy, infection, active infection
ASCITES, BLEEDING, ALLERGY, THYROID DYSFUNCTION, ESOPHAGEAL STENOSIS, INFECTION, COAGULOPATHY, -11
This randomized controlled trial was designed to test whether Betadine (10% povidone-iodine) coating on the PEG tube before implantation could reduce the peristomal infection rate. All patients were referred to the endoscopy unit for PEG implantation from April 2014 to August 2021 at a tertiary medical center. The study had been approved by the Institutional Review Board of Taipei Veterans General Hospital (VGHIRB No. 2013-11-017 C) and trial registration identifier: NCT04249570, ClinicalTrial.gov, 30/01/2020.Patients were excluded from the study if they met the following criteria: the patient’s age was younger than 18 years or older than 100 years; the patient was not eligible for PEG implantation with pull methods, such as massive ascites, coagulopathy, malignancy with stomach invasion, severe left side hepatomegaly, high transverse colon, esophageal stenosis, thyroid dysfunction, history of upper abdominal surgery, or intra-abdomen bleeding; allergy history to cephalosporin or povidone-iodine; antibiotics use within 48 h due to infection, and the patient had an active infection. Randomization assignments were computer-generated and not announced until the trial was completed. To ensure blinding, treatment assignments were contained in sequentially numbered opaque sealed envelopes, which were opened by an independent research staff immediately after the patients’ eligibility was confirmed.